我的生活+的主要目标之一是帮助人们预防新的HIV和其他STI,丙型肝炎和结核病病历的产生。

该应用程序有助于建立医生和HIV感染者之间的匿名沟通。 它可以让您创建简单易行的服药时间表,并设置隐藏和个性化的提醒。

返回
22 十二月 2016, 10:27
2383

Janssen Sciences: Investigational two-drug HIV regimen showed positive results

Janssen Sciences: Investigational two-drug HIV regimen showed positive results - 图片 1

Janssen Sciences Ireland UC announced that two Phase III studies to evaluate the safety and efficacy of switching virologically suppressed patients from a three or four drug (integrase inhibitor-, non-nucleoside reverse transcriptase inhibitor-, or boosted protease inhibitor-based) antiretroviral regimen to the two drug regimen of rilpivirine (Janssen) and dolutegravir (ViiV Healthcare) met the primary endpoint of non inferiority at week 48.

The primary endpoint in both studies was evaluated as the proportion of patients with plasma HIV-1 RNA <50 copies per milliliter (c/mL) at week 48. Detailed study results will be presented at an upcoming scientific meeting. The safety profile for rilpivirine and dolutegravir in the two studies was consistent with the product labelling for each medicine.  

"HIV has become a chronic, long-term condition in many parts of the world thanks to the availability of more than 20 approved medicines. As physicians, and those living with HIV, consider life-long treatment they must balance efficacy and the side effects of treatment," says Lawrence M. Blatt, global R&D head, infectious diseases and vaccines, Janssen. "We are committed to exploring new combination therapies to improve the lives of those facing life-long HIV treatment and these important results for a two-drug regimen support those efforts."  

It is anticipated that regulatory submissions for the investigational two-drug regimen of rilpivirine and dolutegravir as a single tablet will be made in 2017.

http://www.pharmpro.com/news/2016/12/janssen-two-drug-hiv-treatment-receives-positive-results 

作者: Marina Shegay

在社交媒体上分享